Eleni Josephides, Roberta Dunn, Annie-Rose Henry, John Pilling, Karen Harrison-Phipps, Akshay Patel, Shahreen Ahmad, Michael Skwarski, James Spicer, Alexandros Georgiou, Sharmistha Ghosh, Mieke Van Hemelrijck, Eleni Karapanagiotou, Daniel Smith, Andrea Bille
Cancers 2024 Sep 02Stage IIIA-N2 non-small cell lung cancer (NSCLC) poses a significant clinical challenge, with low survival rates despite advances in therapy. The lack of a standardised treatment approach complicates patient management. This study utilises real-world data from Guy's Thoracic Cancer Database to analyse patient outcomes, identify key predictors of overall survival (OS) and disease-free survival (DFS), and address the limitations of randomised controlled trials. This observational, single-centre, non-randomised study analysed 142 patients diagnosed with clinical and pathological T1/2 N2 NSCLC who received curative treatment from 2015 to 2021. Patients were categorised into three groups: Group A (30 patients) underwent surgery for clinical N2 disease, Group B (54 patients) had unsuspected N2 disease discovered during surgery, and Group C (58 patients) received radical chemoradiation or radiotherapy alone (CRT/RT) for clinical N2 disease. Data on demographics, treatment types, recurrence, and survival rates were analysed. The median OS for the cohort was 31 months, with 2-year and 5-year OS rates of 60% and 30%, respectively. Group A had a median OS of 32 months, Group B 36 months, and Group C 25 months. The median DFS was 18 months overall, with Group A at 16 months, Group B at 22 months, and Group C at 17 months. Significant predictors of OS included ECOG performance status, lymphovascular invasion, and histology. No significant differences in OS were found between treatment groups (p = 0.99). This study highlights the complexity and diversity of Stage IIIA-N2 NSCLC, with no single superior treatment strategy identified. The findings underscore the necessity for personalised treatment approaches and multidisciplinary decision-making. Future research should focus on integrating newer therapeutic modalities and conducting multi-centre trials to refine treatment strategies. Collaboration and ongoing data collection are crucial for improving personalised treatment plans and survival outcomes for Stage IIIA-N2 NSCLC patients.
Eleni Josephides, Roberta Dunn, Annie-Rose Henry, John Pilling, Karen Harrison-Phipps, Akshay Patel, Shahreen Ahmad, Michael Skwarski, James Spicer, Alexandros Georgiou, Sharmistha Ghosh, Mieke Van Hemelrijck, Eleni Karapanagiotou, Daniel Smith, Andrea Bille. Real-World Analysis of Survival and Treatment Efficacy in Stage IIIA-N2 Non-Small Cell Lung Cancer. Cancers. 2024 Sep 02;16(17)
PMID: 39272916
View Full Text